2758MO Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers

Himisha Beltran(Dana-Farber Cancer Institute), A.J. Cooper(Memorial Sloan Kettering Cancer Center), Ann W. Gramza(Rapt Therapeutics (United States)), Hirva Mamdani(Wayne State University), John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), A. Dowlati(University Hospitals of Cleveland), K. Nathan Sankar(Cedars-Sinai Medical Center), Prantesh Jain(Roswell Park Comprehensive Cancer Center), Erin L. Schenk(University of Colorado Anschutz Medical Campus), Vassiliki Karantza(Merck & Co., Inc., Rahway, NJ, USA (United States)), M.L. Johnson(Sarah Cannon), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), Rachel E. Sanborn(Providence Portland Medical Center), Aiguo Wang(Anhui Jianzhu University), Satish Vaidya(Daiichi Sankyo (United States))
Annals of Oncology
September 1, 2025
10.1016/j.annonc.2025.08.3369
Cited by 6

Related Papers

Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
|Cell|2014|1.6k
Autophagy in major human diseases
|The EMBO Journal|2021|1.6k